Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis

被引:187
作者
Bonetti, B
Raine, CS
机构
[1] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL NEUROPATHOL,BRONX,NY 10461
[2] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461
[3] YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461
[4] ROSE F KENNEDY CTR RES MENTAL RETARDAT & HUMAN DE,BRONX,NY
[5] OSPED POLICLIN BORGO ROMA,DEPT NEUROL & VIS SCI,NEUROL SECT,VERONA,ITALY
关键词
D O I
10.1002/ana.410420113
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To investigate whether apoptosis is involved in the fare of oligodendrocytes in chronic multiple sclerosis lesions, the pro-apoptotic molecules fas and tumor necrosis factor receptors and the anti-apoptotic molecule bcl-2 were examined by immunohistochemistry, and DNA fragmentation was assessed by an end labeling technique. Fas and both tumor necrosis factor receptors were preferentially expressed on oligodendrocytes in multiple sclerosis lesions, this phenotype being more evident at the lesion edge, The ligand for fast, was constitutively present at high levels on microglia. The anti-apoptotic molecule bcl-2 was selectively expressed on oligodendrocytes in silent lesions and on astrocytes in active lesions. These molecules were also detected in control material, albeit at lower levels, In chronic active lesions, a few inflammatory cells displayed fas reactivity, whereas the majority expressed bcl-2, DNA fragmentation was found in a number of infiltrating cells and some microglia, whereas, with one possible exception, oligodendrocytes showed no evidence of apoptosis. Thus, while apoptosis is involved in the elimination of infiltrating cells, it plays little or no role in oligodendrocyte depletion in multiple sclerosis, a process that may be related to a lyric pathway. In addition, microglia constitutively displayed the ligand for fas, and appeared to be the major effector cell population in the central nervous system.
引用
收藏
页码:74 / 84
页数:11
相关论文
共 53 条
  • [1] Bazzoni F, 1995, J INFLAMM, V45, P221
  • [2] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [3] UNRAVELING FUNCTION IN THE TNF LIGAND AND RECEPTOR FAMILIES
    BEUTLER, B
    VANHUFFEL, C
    [J]. SCIENCE, 1994, 264 (5159) : 667 - 668
  • [4] BONETTI B, 1996, J NEUROPATHOL EXP NE, V55, P641
  • [5] BROSNAN CF, 1992, SEMIN NEUROSCI, V4, P193
  • [6] COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6
  • [7] CROSS AH, 1990, LAB INVEST, V63, P162
  • [8] DSOUZA S, 1995, J NEUROSCI, V15, P7293
  • [9] DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO
  • [10] 2-F